312 related articles for article (PubMed ID: 18726769)
1. Direct to confusion: lessons learned from marketing BRCA testing.
Matloff E; Caplan A
Am J Bioeth; 2008 Jun; 8(6):5-8. PubMed ID: 18726769
[TBL] [Abstract][Full Text] [Related]
2. Genetic testing for vulnerable populations: what kinds of communication we need and do not need.
Schillinger D; Dohan D
Am J Bioeth; 2008 Jun; 8(6):12-4. PubMed ID: 18726772
[No Abstract] [Full Text] [Related]
3. DTC marketing of genetic tests: the perfect storm.
Chapman A
Am J Bioeth; 2008 Jun; 8(6):10-2. PubMed ID: 18726771
[No Abstract] [Full Text] [Related]
4. Why John Stuart Mill would support restriction on DTC marketing of genetic tests.
McGregor JL
Am J Bioeth; 2008 Jun; 8(6):9-10. PubMed ID: 18726770
[No Abstract] [Full Text] [Related]
5. Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing--Atlanta, Denver, Raleigh-Durham, and Seattle, 2003.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2004 Jul; 53(27):603-6. PubMed ID: 15254451
[TBL] [Abstract][Full Text] [Related]
6. Consumer alert: ethical issues raised by the sale of genetic tests directly to consumers.
Wasson K
Am J Bioeth; 2008 Jun; 8(6):16-8. PubMed ID: 18726774
[No Abstract] [Full Text] [Related]
7. Advertising genetic testing for breast cancer.
Weber LJ; Bissell MG
Clin Leadersh Manag Rev; 2004; 18(1):50-1. PubMed ID: 14968755
[No Abstract] [Full Text] [Related]
8. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Forman AD; Hall MJ
Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
[TBL] [Abstract][Full Text] [Related]
9. The double-helix derailed: the story of the BRCA patent.
Matloff ET; Brierley KL
Lancet; 2010 Jul; 376(9738):314-5. PubMed ID: 20674708
[No Abstract] [Full Text] [Related]
10. Actor-network theory: a tool to support ethical analysis of commercial genetic testing.
Williams-Jones B; Graham JE
New Genet Soc; 2003 Dec; 22(3):271-96. PubMed ID: 15115034
[TBL] [Abstract][Full Text] [Related]
11. Scaring up patients.
Ortolon K
Tex Med; 2008 Aug; 104(8):43-6. PubMed ID: 19306543
[No Abstract] [Full Text] [Related]
12. Using lessons learned from BRCA testing and marketing: what lies ahead for whole genome scanning services.
McGowan ML; Fishman JR
Am J Bioeth; 2008 Jun; 8(6):18-20. PubMed ID: 18726775
[No Abstract] [Full Text] [Related]
13. European opposition to exclusive control over predictive breast cancer testing and the inherent implications for U.S. patent law and public policy: a case study of the Myriad Genetics' BRCA patent controversy.
Paradise J
Food Drug Law J; 2004; 59(1):133-54. PubMed ID: 15190928
[No Abstract] [Full Text] [Related]
14. FDA to regulate direct-to-consumer genetic tests.
Brower V
J Natl Cancer Inst; 2010 Nov; 102(21):1610-2, 1617. PubMed ID: 20966430
[No Abstract] [Full Text] [Related]
15. DTC genetic services: a look across the pond.
Borry P; Howard H
Am J Bioeth; 2008 Jun; 8(6):14-6. PubMed ID: 18726773
[No Abstract] [Full Text] [Related]
16. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
Olopade OI
Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
[No Abstract] [Full Text] [Related]
17. Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers.
Cook-Deegan R; DeRienzo C; Carbone J; Chandrasekharan S; Heaney C; Conover C
Genet Med; 2010 Apr; 12(4 Suppl):S15-38. PubMed ID: 20393305
[TBL] [Abstract][Full Text] [Related]
18. Socioeconomic influences on the effects of a genetic testing direct-to-consumer marketing campaign.
Bowen DJ; Harris J; Jorgensen CM; Myers MF; Kuniyuki A
Public Health Genomics; 2010; 13(3):131-42. PubMed ID: 19641293
[TBL] [Abstract][Full Text] [Related]
19. [Prenatal diagnosis for hereditary predisposition to mammary and ovarian carcinoma--defining a position].
Cobben JM; Bröcker-Vriends AH; Leschot NJ
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1461-5. PubMed ID: 12190015
[TBL] [Abstract][Full Text] [Related]
20. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Shulman LP
Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
